Sanofi and its close development partner Regeneron added some positive year-long results to the promising Phase III rheumatoid arthritis data that they’ve been gathering on sarilumab, an antibody that is billed as one of the pharma giant’s top late-stage drug prospects. …read more

Source: Sanofi, Regeneron add positive PhIII data on key RA drug


0 No comments